In recent trading session, Pacific Biosciences of California Inc (NASDAQ:PACB) saw 1.92 million shares changing hands at last check today with its beta currently measuring 1.85. Company’s recent per share price level of $1.60 trading at -$0.04 or -2.44% at last check today assigns it a market valuation of $438.19M. That most recent trading price of PACB’s stock is at a discount of -280.62% from its 52-week high price of $6.09 and is indicating a premium of 27.5% from its 52-week low price of $1.16.
For Pacific Biosciences of California Inc (PACB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.19. Splitting up the data highlights that, out of 11 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Upright in the red during last session for losing -2.44%, in the last five days PACB remained trading in the green while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.60 price level, adding 22.33% to its value on the day. Pacific Biosciences of California Inc’s shares saw a change of -12.57% in year-to-date performance and have moved 8.11% in past 5-day. Pacific Biosciences of California Inc (NASDAQ:PACB) showed a performance of -11.60% in past 30-days.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 46.67% to its recent value today. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -25.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -25.0% for stock’s current value.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
This year revenue growth is estimated to rise 5.07% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 33.66M for the same. And 12 analysts are in estimates of company making revenue of 38.09M in the next quarter. Company posted 38.81M and 36.01M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.31% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 33.64% while estimates for its earnings growth in next 5 years are of 24.02%.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at PACB for having 33.21 million shares of worth $45.5 million. And as of 2024-06-30, it was holding 12.1932 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 26.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6443 of outstanding shares, having a total worth of $35.62 million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 21.16 shares of worth $33.43 million or 7.73% of the total outstanding shares. The later fund manager was in possession of 12.14 shares on Dec 31, 2024, making its stake of worth around $19.18 million in the company or a holder of 4.43% of company’s stock.
